November 22, 2017 |
Blau Farmaceutica has requested permission from Brazil's securities regulator, CVM, to take the company public through an IPO.
In a securities filing, the local biopharmaceutical company named Itau BBA, Morgan Stanley, JPMorgan and Banco Safra as underwriters of the equity offering. ECM sources said a potential offering was likely to materialize in 2018.
Blau recorded net revenues of BRL492m ($151.4m) in the year-ended September, according to figures in the securities filing. For the year-ended
Blau Farmaceutica charts investors, picks banks ahead of potential 2018 equity offering